Boston Scientific Announces Drug-Eluting Stent Market Share Estimates for September and Thi...( TAXUS(R) Atom(TM) in more than 500 a...),Health

TAXUS(R) Atom(TM) in more than 500 accounts Company opening new PROMUS(TM)

accounts

NATICK, Mass., Oct. 14 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced estimated U.S. market shares for September for its two drug-eluting stents (DES), based on preliminary data from Millennium Research Group (MRG), a leading provider of strategic information to the healthcare sector.

Based on the MRG data, the Company estimates its share percentages of the U.S. DES market for September as follows:

-- Boston Scientific's PROMUS(TM) Everolimus-Eluting Coronary Stent System: 25 percent

-- Boston Scientific's TAXUS(R) Express2(TM) Paclitaxel-Eluting Coronary Stent System: 19 percent

The Company said the estimated aggregate U.S. market share for its two drug-eluting stents for the third quarter was approximately 45 percent, based on MRG data. The Company reported the same aggregate U.S. market share for the second quarter.

TAXUS Atom update

The Company said it has introduced its TAXUS(R) Express2(TM) Atom(TM) Paclitaxel-Eluting Coronary Stent System to more than 500 accounts in the United States. The TAXUS Atom stent is the only 2.25 mm diameter drug-eluting stent available in the United States. It was approved by the U.S. Food and Drug Administration (FDA) last month. It provides a drug-eluting stent treatment option for patients with small vessels for whom no DES was previously available. The Company said it is encouraged by the positive reception among clinicians for the TAXUS Atom stent. It said it believes the TAXUS Atom stent is increasing both the use of drug-eluting stents and Boston Scientific's share of the market.

Opening new
'/>"/>